Gábor Tóth

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Gábor Tóth, Árpád Szöőr, L Simón et al. · mAbs · 2016 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies

Árpád Szöőr, Gábor Tóth, Barbara Zsebik et al. · Cancer Letters · 2020 · 100 citations · Full text

Medicine, Immunology, Oncology +17

A pilot study of the translation, cultural adaptation and validation of the EORTC head and neck cancer quality of life questionnaire module (QLQ-H&N35) for use in Japan

Gábor Tóth, Toshihiro Sakaguchi, Yasukazu Mikami et al. · Auris Nasus Larynx · 2005 · 38 citations

Pharmacy, Oncology, Cancer Symptom Management +16

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts

Gábor Tóth, János Szöllõsi, Hinrich Abken et al. · International Journal of Molecular Sciences · 2020 · 38 citations · Full text

Life Sciences, Immunology, Oncology +17

Quantitating ADCC against adherent cells: Impedance‐based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response

Gábor Tóth, János Szöllõsi, György Vereb · Cytometry Part A · 2017 · 16 citations · Full text

Life Sciences, Immunology, Pharmacology +13